Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Inclusion Criteria: * The experienced participants who were treated previously with (SOF/DCV) , (SOF/SMV), (SOF/RBV), or (SOF/pegINF/RBV). * The presence of compensated liver cirrhosis was documented by ultrasonographic examination, liver biopsy, results of Fibroscan or FIB-4 score, and laboratory markers, like FIB-4 \> 3.25 (advanced fibrosis or cirrhosis), albumin \< 3.5, total bilirubin \> 1.2, and also confirmed by clinical characteristics such as lower limb edema, splenomegaly, esophageal varices. Exclusion Criteria: * liver disease of non-HCV GT4 etiology, coinfection with hepatitis B or HIV * poorly controlled diabetes (HbA1C \> 8) * participants, hepatocellular carcinoma, a history of extrahepatic malignancy in the 5 years prior to the study * renal failure * evidence of hepatic decompensation * blood picture abnormalities such as anemia (hemoglobin concentration of \< 10 g/dL) * thrombocytopenia (platelets count \< 50,000 cells/mm3). * major severe illness such as congestive heart failure and respiratory failure.